NRXP
NRx Pharmaceuticals, Inc. NASDAQ Listed Dec 4, 2017$2.90
+1.58%
vs $2.85
Mkt Cap $125.3M
52w Low $1.62
37.1% of range
52w High $5.06
50d MA $3.35
200d MA $2.93
P/E (TTM)
—
EV/EBITDA
—
P/B
—
Debt/Equity
-0.0x
ROE
179.6%
P/FCF
-4.3x
RSI (14)
21.60
ATR (14)
$0.16
Beta
1.83
50d MA
$3.35
200d MA
$2.93
Avg Volume
680.0K
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
1201 Orange Street · Wilmington, DE 19801 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 14, 2026 | BMO | -0.11 | -0.44 | -312.5% | 3.34 | +0.9% | -2.1% | +4.9% | +0.3% | -3.2% | +5.4% | — |
| May 18, 2026 | BMO | -0.05 | -0.04 | +20.0% | 3.28 | +3.4% | -4.9% | -2.9% | -2.0% | +3.0% | +5.2% | — |
| May 15, 2026 | BMO | -0.05 | -0.04 | +20.0% | 3.21 | +1.2% | +2.2% | -4.9% | -2.9% | -2.0% | +3.0% | — |
| Mar 23, 2026 | BMO | -0.09 | 0.19 | +311.1% | 1.77 | +6.8% | +20.3% | +13.1% | -1.2% | -8.0% | -4.6% | — |
| Nov 14, 2025 | BMO | -0.11 | -0.18 | -63.6% | 2.49 | -8.0% | -15.3% | +8.1% | -6.6% | -4.7% | +4.9% | — |
| Aug 18, 2025 | BMO | -0.15 | -0.98 | -552.6% | 2.89 | -1.0% | -4.5% | -9.1% | +4.4% | -3.4% | +4.3% | — |
| May 15, 2025 | BMO | -0.30 | -0.34 | -13.3% | 2.40 | -2.1% | +2.1% | -0.4% | +13.9% | -5.4% | +2.3% | — |
| Mar 14, 2025 | BMO | -0.20 | -0.30 | -50.0% | 2.35 | +0.0% | -12.8% | +7.3% | -0.9% | -5.0% | +0.5% | — |
| Nov 14, 2024 | BMO | -0.81 | -0.15 | +81.5% | 1.16 | +0.0% | +2.6% | +9.2% | -5.4% | -1.6% | +1.7% | — |
| Aug 14, 2024 | BMO | -0.81 | -0.75 | +7.4% | 1.86 | +3.8% | -6.5% | -0.6% | +0.0% | +5.8% | +3.8% | — |
| May 14, 2024 | BMO | -0.55 | -0.74 | -34.5% | 3.18 | +1.6% | +1.6% | +9.0% | +0.6% | +14.7% | -4.9% | — |
| Mar 29, 2024 | BMO | -0.70 | -0.50 | +28.6% | 4.72 | — | — | — | -4.8% | -5.2% | +9.7% | — |
| Nov 13, 2023 | BMO | -1.10 | -0.70 | +36.4% | 3.36 | +4.2% | +4.2% | -7.1% | -6.8% | +2.0% | +0.6% | — |
| Aug 14, 2023 | BMO | -1.40 | -1.20 | +14.3% | 3.31 | -1.5% | +2.7% | -3.8% | +2.4% | -3.0% | -2.2% | — |
| May 16, 2023 | BMO | -1.50 | -1.30 | +13.3% | 6.46 | +0.6% | +5.3% | +0.0% | +5.9% | -4.9% | -2.9% | — |
| Mar 30, 2023 | BMO | -1.40 | -1.50 | -7.1% | 7.37 | -0.9% | -10.6% | -5.6% | -6.9% | -5.0% | +5.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.94 | $2.99 | +1.7% | +3.1% | -2.6% | -1.4% | +2.4% | +3.7% |
| Apr 27 | Ascendiant Capital | Maintains | Buy → Buy | — | $2.94 | $2.99 | +1.7% | +3.1% | -2.6% | -1.4% | +2.4% | +3.7% |
| Apr 23 | D. Boral Capital | Maintains | Buy → Buy | — | $2.97 | $2.96 | -0.3% | -4.4% | +3.5% | +3.1% | -2.6% | -1.4% |
| Apr 20 | D. Boral Capital | Maintains | Buy → Buy | — | $2.55 | $2.55 | +0.0% | +25.5% | -7.8% | +0.7% | -4.4% | +3.5% |
| Mar 24 | BTIG | Maintains | Buy → Buy | — | $1.77 | $1.89 | +6.8% | +20.3% | +13.1% | -1.2% | -8.0% | -4.6% |
| Mar 24 | D. Boral Capital | Maintains | Buy → Buy | — | $1.77 | $1.89 | +6.8% | +20.3% | +13.1% | -1.2% | -8.0% | -4.6% |
| Mar 17 | D. Boral Capital | Maintains | Buy → Buy | — | $2.08 | $2.13 | +2.4% | -6.2% | -2.6% | -3.2% | +0.5% | -4.3% |
| Mar 16 | D. Boral Capital | Maintains | Buy → Buy | — | $1.86 | $1.95 | +4.8% | +11.8% | -6.2% | -2.6% | -3.2% | +0.5% |
| Mar 9 | D. Boral Capital | Maintains | Buy → Buy | — | $1.70 | $1.64 | -3.5% | +1.8% | +4.6% | +1.7% | -2.2% | +3.3% |
| Mar 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.81 | $1.77 | -2.2% | -0.6% | +3.9% | -5.3% | -4.0% | +1.8% |
| Feb 18 | BTIG | Maintains | Buy → Buy | — | $1.80 | $1.79 | -0.6% | -1.1% | +3.4% | +0.0% | -4.3% | +7.4% |
| Feb 17 | D. Boral Capital | Maintains | Buy → Buy | — | $1.80 | $1.80 | +0.0% | +0.0% | -1.1% | +3.4% | +0.0% | -4.3% |
| Jan 15 | BTIG | Maintains | Buy → Buy | — | $2.15 | $2.16 | +0.5% | +0.0% | +5.6% | -4.0% | +3.7% | +3.5% |
| Jan 5 | D. Boral Capital | Maintains | Buy → Buy | — | $2.62 | $2.62 | +0.0% | -8.0% | -0.8% | +2.5% | -4.9% | -4.7% |
| Jan 2 | Ascendiant Capital | Maintains | Buy → Buy | — | $2.71 | $2.75 | +1.5% | -3.3% | -8.0% | -0.8% | +2.5% | -4.9% |
| Dec 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.98 | $2.00 | +1.0% | +6.1% | +8.6% | -4.4% | +8.7% | +1.7% |
| Dec 3 | D. Boral Capital | Maintains | Buy → Buy | — | $2.27 | $2.27 | +0.0% | +6.2% | +1.2% | -3.3% | -4.2% | +4.0% |
| Dec 3 | BTIG | Maintains | Buy → Buy | — | $2.27 | $2.27 | +0.0% | +6.2% | +1.2% | -3.3% | -4.2% | +4.0% |
| Dec 2 | D. Boral Capital | Maintains | Buy → Buy | — | $2.39 | $2.45 | +2.5% | -5.0% | +6.2% | +1.2% | -3.3% | -4.2% |
| Nov 17 | D. Boral Capital | Maintains | Buy → Buy | — | $2.49 | $2.29 | -8.0% | -15.3% | +8.1% | -6.6% | -4.7% | +4.9% |
| Nov 10 | D. Boral Capital | Maintains | Buy → Buy | — | $2.45 | $2.51 | +2.4% | +3.7% | -2.0% | +6.0% | -1.9% | -3.9% |
| Oct 30 | Ascendiant Capital | Maintains | Buy → Buy | — | $3.05 | $3.04 | -0.3% | -1.0% | +2.6% | -8.1% | -3.9% | -2.9% |
| Oct 21 | D. Boral Capital | Maintains | Buy → Buy | — | $3.31 | $3.39 | +2.4% | -3.0% | -1.9% | +1.6% | -1.6% | -0.3% |
| Oct 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.17 | $3.18 | +0.3% | -4.1% | +4.6% | +4.1% | -3.0% | -1.9% |
| Oct 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.30 | $3.31 | +0.3% | +1.2% | -0.3% | -1.8% | +2.4% | +9.6% |
| Sep 29 | D. Boral Capital | Maintains | Buy → Buy | — | $2.95 | $3.03 | +2.7% | +10.2% | +1.5% | +1.2% | -0.3% | -1.8% |
| Sep 25 | D. Boral Capital | Maintains | Buy → Buy | — | $2.99 | $2.99 | +0.0% | -2.7% | +1.4% | +10.2% | +1.5% | +1.2% |
| Sep 8 | D. Boral Capital | Maintains | Buy → Buy | — | $2.75 | $2.88 | +4.7% | +3.3% | +10.9% | -5.7% | -3.0% | -2.8% |
| Aug 22 | D. Boral Capital | Maintains | Buy → Buy | — | $2.53 | $2.59 | +2.4% | +4.3% | +1.9% | -2.2% | -1.9% | -2.3% |
| Aug 19 | D. Boral Capital | Maintains | Buy → Buy | — | $2.76 | $2.83 | +2.5% | -9.1% | +4.4% | -3.4% | +4.3% | +1.9% |
| Aug 11 | D. Boral Capital | Maintains | Buy → Buy | — | $2.52 | $2.60 | +3.2% | -7.9% | +3.0% | +5.9% | +5.5% | +8.2% |
| Aug 4 | D. Boral Capital | Maintains | Buy → Buy | — | $2.59 | $2.68 | +3.5% | +5.0% | -2.9% | -6.8% | +0.0% | +2.4% |
| Jun 23 | D. Boral Capital | Maintains | Buy → Buy | — | $3.26 | $3.19 | -2.1% | -4.9% | +3.9% | +1.6% | +7.0% | -2.3% |
| Jun 20 | D. Boral Capital | Maintains | Buy → Buy | — | $3.23 | $3.34 | +3.4% | +0.9% | -4.9% | +3.9% | +1.6% | +7.0% |
| Jun 6 | D. Boral Capital | Maintains | Buy → Buy | — | $2.94 | $3.02 | +2.7% | +11.2% | +12.2% | -0.5% | -4.7% | -1.1% |
| May 16 | D. Boral Capital | Maintains | Buy → Buy | — | $2.40 | $2.35 | -2.1% | +2.1% | -0.4% | +13.9% | -5.4% | +2.3% |
| Apr 30 | D. Boral Capital | Maintains | Buy → Buy | — | $2.06 | $2.08 | +1.0% | +2.9% | -1.9% | -1.4% | -1.0% | -5.4% |
| Apr 29 | Ascendiant Capital | Maintains | Buy → Buy | — | $2.10 | $2.07 | -1.4% | -1.9% | +2.9% | -1.9% | -1.4% | -1.0% |
| Mar 31 | D. Boral Capital | Maintains | Buy → Buy | — | $2.03 | $2.04 | +0.5% | +1.0% | -5.4% | +3.6% | -7.0% | -4.3% |
| Mar 24 | D. Boral Capital | Maintains | Buy → Buy | — | $2.08 | $2.20 | +5.8% | -0.5% | -2.9% | +3.0% | +0.0% | -1.9% |
| Mar 20 | D. Boral Capital | Maintains | Buy → Buy | — | $2.18 | $2.18 | +0.0% | -5.0% | +0.5% | -0.5% | -2.9% | +3.0% |
| Mar 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.18 | $2.18 | +0.0% | -5.0% | +0.5% | -0.5% | -2.9% | +3.0% |
| Mar 17 | D. Boral Capital | Maintains | Buy → Buy | — | $2.35 | $2.35 | +0.0% | -12.8% | +7.3% | -0.9% | -5.0% | +0.5% |
| Mar 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.07 | $2.09 | +1.0% | +13.5% | -12.8% | +7.3% | -0.9% | -5.0% |
| Jan 28 | D. Boral Capital | Maintains | Buy → Buy | — | $2.85 | $2.84 | -0.4% | +24.6% | -11.5% | -4.8% | +1.0% | -7.3% |
| Jan 6 | D. Boral Capital | Maintains | Buy → Buy | — | $2.69 | $2.92 | +8.6% | +30.5% | +32.8% | -19.3% | +29.0% | +1.2% |
| Jan 2 | D. Boral Capital | Maintains | Buy → Buy | — | $2.20 | $2.12 | -3.6% | +35.9% | -10.0% | +30.5% | +32.8% | -19.3% |
| Dec 31 | D. Boral Capital | Maintains | Buy → Buy | — | $1.53 | $1.55 | +1.3% | +43.8% | +35.9% | -10.0% | +30.5% | +32.8% |
| Dec 2 | Ascendiant Capital | Maintains | Buy → Buy | — | $1.31 | $1.33 | +1.5% | +3.1% | -6.7% | -3.2% | -2.5% | +2.5% |
| Nov 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.26 | $1.26 | +0.0% | +4.0% | -3.1% | +1.6% | +1.6% | +3.1% |
No insider trades available.
8-K · 8.01
!! High
NRx Pharmaceuticals, Inc. -- 8-K 8.01: Material Event / Announcement
Sep 16
8-K · 7.01
! Medium
NRx Pharmaceuticals, Inc. -- 8-K 7.01: Regulation FD Disclosure
Sep 14
8-K · 2.02
!! High
NRx Pharmaceuticals, Inc. -- 8-K 2.02: Earnings Results
NRx Pharmaceuticals reported earnings results, with detailed financial performance available in the attached press release exhibit.
Aug 17
8-K · 7.01
! Medium
NRx Pharmaceuticals, Inc. -- 8-K 7.01: Regulation FD Disclosure
Aug 7
8-K · 8.01
!! High
NRx Pharmaceuticals, Inc. -- 8-K 8.01: Material Event / Announcement
Jul 22
8-K · 8.01
!! High
NRx Pharmaceuticals, Inc. -- 8-K 8.01: Material Event / Announcement
Jun 2
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
NRXP stockholders approved the company's independent auditor for fiscal 2025, indicating routine governance operations and no accounting firm controversy that could signal financial reporting risks.
Mar 24
8-K · 8.01
!! High
NRX Pharmaceuticals, Inc. -- 8-K 8.01: Material Event / Announcement
NRX Pharmaceuticals activated its S-3 shelf registration effective December 22, 2025, enabling the company to conduct future equity offerings and raise capital more efficiently.
Feb 17
8-K · 8.01
!! High
NRX Pharmaceuticals, Inc. -- 8-K 8.01: Material Event / Announcement
NRX Pharmaceuticals disclosed a material announcement via press release filing, though the specific details require reviewing the attached exhibit to assess investment implications.
Feb 17
8-K · 5.02
!!! Very High
Longeveron Inc. -- 8-K 5.02: Executive Change
Longeveron appointed Stephen H. Willard as Chief Executive Officer, signaling new leadership that may reshape company strategy and investor confidence in the regenerative medicine firm.
Feb 13
8-K
NRX Pharmaceuticals, Inc. -- 8-K Filing
NRX Pharmaceuticals' board gained a director with healthcare IT expertise through SureTest, Inc., potentially strengthening governance in clinical technology and automation sectors.
Feb 2
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Capital Management Llc | 1,618,159 | $7M | Added | Jun 2026 |
| 2 | Citadel Advisors Llc | 1,360,086 | $6M | New | Jun 2026 |
| 3 | Commonwealth Equity Services, Llc | 366,631 | $994K | New | Dec 2025 |
| 4 | Blackrock, Inc. | 220,460 | $902K | New | Jun 2026 |
| 5 | Bleakley Financial Group, Llc | 117,216 | $479K | New | Jun 2026 |
| 6 | Chicago Partners Investment Group Llc | 46,388 | $191K | New | Jun 2026 |
| 7 | Quadrature Capital Ltd | 43,605 | $178K | New | Jun 2026 |
| 8 | One Wealth Management Investment & Advisory Services, Llc | 43,309 | $177K | New | Jun 2026 |
| 9 | Renaissance Technologies Llc | 38,600 | $158K | New | Jun 2026 |
| 10 | Two Sigma Investments, Lp | 26,429 | $108K | New | Jun 2026 |
| 11 | Jane Street Group, Llc | 38,065 | $103K | Reduced | Dec 2025 |
| 12 | Northern Trust Corp | 43,469 | $93K | Added | Mar 2026 |
| 13 | Axq Capital, Lp | 33,211 | $71K | New | Mar 2026 |
| 14 | Persistent Asset Partners Ltd | 16,326 | $67K | New | Jun 2026 |
| 15 | Sjbenen Advisory, Llc | 15,000 | $58K | — | Jun 2026 |
| 16 | Morgan Stanley | 20,058 | $54K | Reduced | Dec 2025 |
| 17 | Ubs Group Ag | 25,227 | $54K | Added | Mar 2026 |
| 18 | Ethos Financial Group, Llc | 15,900 | $51K | New | Jun 2026 |
| 19 | Millennium Management Llc | 12,305 | $50K | New | Jun 2026 |
| 20 | Citigroup Inc | 5,992 | $25K | New | Jun 2026 |
Mutual Funds / ETFs (N-PORT) — Top 7
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | AdvisorShares Psychedelics ETF | 659,018 | $3M | Jun 2026 |
| 2 | Fidelity Series Total Market Index Fund | 48,123 | $213K | May 2026 |
| 3 | Fidelity Extended Market Index Fund | 108,992 | $203K | Feb 2026 |
| 4 | iShares Micro-Cap ETF | 66,109 | $141K | Mar 2026 |
| 5 | Fidelity Total Market Index Fund | 30,812 | $136K | May 2026 |
| 6 | Fidelity Nasdaq Composite Index Fund | 21,976 | $41K | Feb 2026 |
| 7 | Blackstone Alternative Multi-Strategy Fund | -1,211 | $-4953 | Jun 2026 |
Valuation
Market Cap
$125.3M
Enterprise Value
$53.5M
P/E (TTM)
—
Forward P/E
2.58x
PEG Ratio
0.05x
P/B
—
P/S
18.26x
P/FCF
-4.32x
EV/EBITDA
—
Shares Out
21.4M
Financials (TTM)
Revenue
$3.4M
Net Income
-$23.5M
EBITDA
-$22.0M
Free Cash Flow
-$14.1M
Op Cash Flow
-$14.1M
EPS Basic
$-1.34
EPS Diluted
$-0.74
EPS Forward
$1.12
Gross Margin
32.7%
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$13.0M
Total Liab.
$28.9M
Total Equity
-$15.9M
Cash
$7.8M
LT Debt
$315K
Book Value/Sh
$-0.74
Debt/Equity
-0.04x
Current Ratio
0.31
Quick Ratio
0.31
Returns & Growth
ROE
179.6%
ROA
-220.9%
ROIC
106.0%
Rev Growth YoY
+0.0%
EPS Growth YoY
+43.9%
Price Returns
2W
-15.9%
1M
-17.6%
3M
-26.4%
6M
+29.5%
12M
-14.4%
Technicals
52W High
$5.06
52W Low
$1.62
50d MA
$3.35
200d MA
$2.93
RSI (14)
21.60
ATR (14)
$0.16
Beta
1.83
Avg Volume
680K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$2.00
High
$2.00
Low
$2.00
Median
$2.00
Data updated apr 26, 2026 3:47pm
· Source: financialmodelingprep.com